phosphonoacetic acid has been researched along with Cytomegalovirus Infections in 126 studies
Phosphonoacetic Acid: A simple organophosphorus compound that inhibits DNA polymerase, especially in viruses and is used as an antiviral agent.
phosphonoacetic acid : A member of the class of phosphonic acids that is phosphonic acid in which the hydrogen attached to the phosphorous is replaced by a carboxymethyl group.
Cytomegalovirus Infections: Infection with CYTOMEGALOVIRUS, characterized by enlarged cells bearing intranuclear inclusions. Infection may be in almost any organ, but the salivary glands are the most common site in children, as are the lungs in adults.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In a controlled trial of foscarnet in the treatment of cytomegalovirus (CMV) retinitis in patients with the acquired immunodeficiency syndrome (AIDS), patients with non-immediately sight-threatening lesions were randomized to receive immediate treatment with foscarnet or foscarnet treatment delayed until the first signs of retinitis progression." | 9.07 | Design of a randomized controlled trial of foscarnet in patients with cytomegalovirus retinitis associated with acquired immunodeficiency syndrome. ( Polis, MA, 1992) |
| "To evaluate foscarnet sodium in treating cytomegalovirus retinitis in patients with AIDS." | 9.07 | A randomized, controlled trial of foscarnet in the treatment of cytomegalovirus retinitis in patients with AIDS. ( Baird, BF; Davey, RT; Davis, M; De Smet, MD; Falloon, J; Kovacs, JA; Palestine, AG; Polis, MA; Zunich, KM; Zurlo, JJ, 1991) |
| "Circulating human immunodeficiency virus (HIV) p24 antigen levels were measured in 22 AIDS patients who had detectable serum antigen at baseline after induction and maintenance therapy of foscarnet for cytomegalovirus retinitis in phase I/II multicenter trials." | 9.07 | Effect of foscarnet therapy on human immunodeficiency virus p24 antigen levels in AIDS patients with cytomegalovirus retinitis. ( Causey, DM; Davis, RB; Grieco, MH; Hooton, TM; Jacobson, MA; McKinley, GF; Parenti, DM; Reddy, MM; van der Horst, CM, 1992) |
| "These results suggest that for patients with AIDS, and cytomegalovirus retinitis, treatment with foscarnet offers a survival advantage over treatment with ganciclovir, although the patients may not tolerate foscarnet as well as ganciclovir." | 9.07 | Mortality in patients with the acquired immunodeficiency syndrome treated with either foscarnet or ganciclovir for cytomegalovirus retinitis. ( , 1992) |
| "Ganciclovir and Foscarnet were compared in an open randomised trial as treatment and secondary prophylaxis of cytomegalovirus (CMV) retinitis in patients with AIDS." | 9.07 | Foscarnet and Ganciclovir in the treatment of CMV retinitis in AIDS patients: a randomised comparison. ( Gazzard, BG; Harman, C; Mathalone, B; Mitchell, S; Moyle, G, 1992) |
| "Intravenous foscarnet was given on an emergency basis to 30 immunosuppressed patients with cytomegalovirus (CMV) disease, of whom 28 were organ transplant recipients." | 9.06 | Sensitivity of cytomegalovirus to intravenous foscarnet treatment. ( Akesson-Johansson, A; Lernestedt, JO; Lönnqvist, B; Ringdén, O; Wahren, B, 1986) |
| "The use of ganciclovir in the treatment of cytomegalovirus (CMV) retinitis in patients with acquired immunodeficiency syndrome (AIDS) is limited by marrow toxicity and by the development of resistance to this agent in CMV strains capable of causing progressive disease." | 8.78 | Maintenance therapy for cytomegalovirus retinitis in patients with acquired immunodeficiency syndrome: foscarnet. ( Jacobson, MA, 1992) |
| "The pyrophosphate analogue, foscarnet, selectively inhibits the DNA polymerase of human herpes viruses, including cytomegalovirus, and the reverse transcriptase of HIV." | 8.78 | Foscarnet. A review of its antiviral activity, pharmacokinetic properties and therapeutic use in immunocompromised patients with cytomegalovirus retinitis. ( Chrisp, P; Clissold, SP, 1991) |
| "Induction regimens of foscarnet and ganciclovir are highly effective in arresting cytomegalovirus (CMV) retinitis in patients with AIDS." | 8.78 | Foscarnet and ganciclovir in the treatment of cytomegalovirus retinitis. ( Polis, MA, 1992) |
| "Ganciclovir and foscarnet are both effective for cytomegalovirus retinitis in patients with acquired immunodeficiency syndrome, but the benefits of either agent given alone are limited." | 7.68 | Treatment of aggressive cytomegalovirus retinitis with ganciclovir in combination with foscarnet in a child infected with human immunodeficiency virus. ( Butler, KM; De Smet, MD; Husson, RN; Jarosinski, P; Lovato, G; Manjunath, K; Montrella, K; Mueller, B; Nussenblatt, RB; Pizzo, PA, 1992) |
| "Foscarnet is an investigational antiviral agent that has been used effectively in the treatment of cytomegalovirus (CMV) retinitis in AIDS patients." | 7.68 | Successful foscarnet therapy for cytomegalovirus retinitis in an AIDS patient undergoing hemodialysis: rationale for empiric dosing and plasma level monitoring. ( Gambertoglio, JG; Graziani, AL; Grunwald, JE; MacGregor, RR; Weiss, R, 1991) |
| "Foscarnet, administered via a central line, was used for the treatment of 18 episodes of cytomegalovirus (CMV) esophageal ulceration in 15 patients, and in the treatment of 27 episodes of CMV colitis in 22 patients." | 7.68 | Foscarnet in the treatment of cytomegalovirus infection of the esophagus and colon in patients with the acquired immune deficiency syndrome. ( Connolly, GM; Gazzard, BG; Hawkins, DA; Nelson, MR, 1991) |
| "Infections caused by cytomegalovirus (CMV) resistant in vitro to ganciclovir, defined as requiring greater than 6 mumols of ganciclovir for ED50 have developed in some AIDS patients with progressive CMV retinitis despite chronic ganciclovir therapy." | 7.68 | Foscarnet therapy for ganciclovir-resistant cytomegalovirus retinitis in patients with AIDS. ( Drew, WL; Feinberg, J; Jacobson, MA; Miner, RD; O'Donnell, JJ; Parenti, D; Whitmore, PV, 1991) |
| "Ten patients with acquired immunodeficiency syndrome with newly diagnosed cytomegalovirus (CMV) retinitis were treated with an induction regimen of intravenous foscarnet, 60 mg/kg of body weight, administered as a 2-h infusion and repeated every 8 h for 14 days." | 7.67 | Foscarnet treatment of cytomegalovirus retinitis in patients with the acquired immunodeficiency syndrome. ( Jacobson, MA; Mills, J; O'Donnell, JJ, 1989) |
| "Eight patients, 7 renal and 1 combined renal and pancreas allograft recipients with generalized cytomegalovirus (CMV) infection were treated with continuous intravenous foscarnet infusion (0." | 7.67 | Evaluation by immune scanning electron microscopy of foscarnet treatment of cytomegalovirus infection in patients with renal transplants. ( Akesson-Johansson, A; Andersson, J; Brattström, C, 1989) |
| " Following allogeneic bone marrow transplantation, he developed cytomegalovirus retinitis, which was treated successfully with trisodium phosphonoformate (foscarnet)." | 7.67 | Foscarnet as treatment for cytomegalovirus retinitis following bone marrow transplantation. ( Arthur, C; Ganly, PS; Goldman, JM; Schulenburg, WE, 1988) |
| "Treatment with Foscarnet may be initially effective, but does not eliminate cytomegalovirus infection." | 6.66 | Cytomegalovirus colitis and oesophageal ulceration in the context of AIDS: clinical manifestations and preliminary report of treatment with Foscarnet (phosphonoformate). ( Barrison, I; Boylston, A; Forster, S; Jeffries, DJ; Pinching, AJ; Thom, S; Unwin, R; Weber, JN, 1987) |
| "Foscarnet has a low solubility and a high degree of ionization at physiologic pH, requiring it to be administered in higher doses and larger volumes." | 6.38 | Approaches to the treatment of cytomegalovirus retinitis: ganciclovir and foscarnet. ( Jacobson, MA; O'Donnell, JJ, 1991) |
| "Foscarnet was discontinued because of adverse events in 3 (3%) of 97 patients, with treatment being stopped in 2 patients because of renal insufficiency and in 1 patient because of an acute neurologic disorder." | 5.28 | Foscarnet induction therapy for cytomegalovirus retinitis in AIDS: comparison of twice-daily and three-times-daily regimens. ( Brancon, C; Caumes, E; Cochereau-Massin, I; Dahan, R; Dohin, E; Gentilini, M; Katlama, C; Robinet, M; Rogeaux, O, 1992) |
| "Foscarnet was given as a continuous intravenous infusion." | 5.28 | Foscarnet for treatment of cytomegalovirus infections in bone marrow transplant recipients. ( Aschan, J; Ljungman, P; Lönnqvist, B; Ohlman, S; Ringdén, O, 1992) |
| "Eight patients with acquired immunodeficiency syndrome and serious CMV retinitis received 2-h intravenous infusions of foscarnet at a dosage of 60 mg/kg of body weight every 8 h for 14 days." | 5.28 | Pharmacokinetics of intermittently administered intravenous foscarnet in the treatment of acquired immunodeficiency syndrome patients with serious cytomegalovirus retinitis. ( Aweeka, F; Gambertoglio, J; Jacobson, MA; Mills, J, 1989) |
| " Adverse effects, such as decreased haemoglobin, decreased renal function and increased serum calcium, were observed in a few patients only." | 5.27 | Pharmacokinetics, safety and preliminary clinical experiences using foscarnet in the treatment of cytomegalovirus infections in bone marrow and renal transplant recipients. ( Ahlmén, J; Klintmalm, G; Lernestedt, JO; Lönnqvist, B; Paulin, T; Ringdén, O; Wahren, B, 1986) |
| "In a controlled trial of foscarnet in the treatment of cytomegalovirus (CMV) retinitis in patients with the acquired immunodeficiency syndrome (AIDS), patients with non-immediately sight-threatening lesions were randomized to receive immediate treatment with foscarnet or foscarnet treatment delayed until the first signs of retinitis progression." | 5.07 | Design of a randomized controlled trial of foscarnet in patients with cytomegalovirus retinitis associated with acquired immunodeficiency syndrome. ( Polis, MA, 1992) |
| "These results suggest that for patients with AIDS, and cytomegalovirus retinitis, treatment with foscarnet offers a survival advantage over treatment with ganciclovir, although the patients may not tolerate foscarnet as well as ganciclovir." | 5.07 | Mortality in patients with the acquired immunodeficiency syndrome treated with either foscarnet or ganciclovir for cytomegalovirus retinitis. ( , 1992) |
| "To evaluate foscarnet sodium in treating cytomegalovirus retinitis in patients with AIDS." | 5.07 | A randomized, controlled trial of foscarnet in the treatment of cytomegalovirus retinitis in patients with AIDS. ( Baird, BF; Davey, RT; Davis, M; De Smet, MD; Falloon, J; Kovacs, JA; Palestine, AG; Polis, MA; Zunich, KM; Zurlo, JJ, 1991) |
| "Circulating human immunodeficiency virus (HIV) p24 antigen levels were measured in 22 AIDS patients who had detectable serum antigen at baseline after induction and maintenance therapy of foscarnet for cytomegalovirus retinitis in phase I/II multicenter trials." | 5.07 | Effect of foscarnet therapy on human immunodeficiency virus p24 antigen levels in AIDS patients with cytomegalovirus retinitis. ( Causey, DM; Davis, RB; Grieco, MH; Hooton, TM; Jacobson, MA; McKinley, GF; Parenti, DM; Reddy, MM; van der Horst, CM, 1992) |
| "Ganciclovir and Foscarnet were compared in an open randomised trial as treatment and secondary prophylaxis of cytomegalovirus (CMV) retinitis in patients with AIDS." | 5.07 | Foscarnet and Ganciclovir in the treatment of CMV retinitis in AIDS patients: a randomised comparison. ( Gazzard, BG; Harman, C; Mathalone, B; Mitchell, S; Moyle, G, 1992) |
| "Intravenous foscarnet was given on an emergency basis to 30 immunosuppressed patients with cytomegalovirus (CMV) disease, of whom 28 were organ transplant recipients." | 5.06 | Sensitivity of cytomegalovirus to intravenous foscarnet treatment. ( Akesson-Johansson, A; Lernestedt, JO; Lönnqvist, B; Ringdén, O; Wahren, B, 1986) |
| "Induction regimens of foscarnet and ganciclovir are highly effective in arresting cytomegalovirus (CMV) retinitis in patients with AIDS." | 4.78 | Foscarnet and ganciclovir in the treatment of cytomegalovirus retinitis. ( Polis, MA, 1992) |
| "The use of ganciclovir in the treatment of cytomegalovirus (CMV) retinitis in patients with acquired immunodeficiency syndrome (AIDS) is limited by marrow toxicity and by the development of resistance to this agent in CMV strains capable of causing progressive disease." | 4.78 | Maintenance therapy for cytomegalovirus retinitis in patients with acquired immunodeficiency syndrome: foscarnet. ( Jacobson, MA, 1992) |
| " The antiviral agents ganciclovir and foscarnet are effective against CMV retinitis and gastrointestinal diseases, although dose-limiting adverse effects and the need for long-term maintenance therapy may hinder their use in many patients." | 4.78 | Treatment and prophylaxis of cytomegalovirus disease. ( Jacobson, PA; Levinson, ML, 1992) |
| "The pyrophosphate analogue, foscarnet, selectively inhibits the DNA polymerase of human herpes viruses, including cytomegalovirus, and the reverse transcriptase of HIV." | 4.78 | Foscarnet. A review of its antiviral activity, pharmacokinetic properties and therapeutic use in immunocompromised patients with cytomegalovirus retinitis. ( Chrisp, P; Clissold, SP, 1991) |
| "Drug-resistant human cytomegalovirus (HCMV) strains were selected in human embryonic lung (HEL) fibroblasts under pressure of the (S)-3-hydroxy-2-phosphonylmethoxypropyl (HPMP) derivatives of cytosine (HPMPC) and adenine (HPMPA), the 2-phosphonylmethoxyethyl (PME) derivative of 2,6-diaminopurine (PMEDAP), ganciclovir (GCV), acyclovir (ACV), and foscarnet (PFA)." | 3.69 | Patterns of resistance and sensitivity to antiviral compounds of drug-resistant strains of human cytomegalovirus selected in vitro. ( Andrei, G; De Clercq, E; Snoeck, R, 1996) |
| "Infections caused by cytomegalovirus (CMV) resistant in vitro to ganciclovir, defined as requiring greater than 6 mumols of ganciclovir for ED50 have developed in some AIDS patients with progressive CMV retinitis despite chronic ganciclovir therapy." | 3.68 | Foscarnet therapy for ganciclovir-resistant cytomegalovirus retinitis in patients with AIDS. ( Drew, WL; Feinberg, J; Jacobson, MA; Miner, RD; O'Donnell, JJ; Parenti, D; Whitmore, PV, 1991) |
| "Ganciclovir and foscarnet are both effective for cytomegalovirus retinitis in patients with acquired immunodeficiency syndrome, but the benefits of either agent given alone are limited." | 3.68 | Treatment of aggressive cytomegalovirus retinitis with ganciclovir in combination with foscarnet in a child infected with human immunodeficiency virus. ( Butler, KM; De Smet, MD; Husson, RN; Jarosinski, P; Lovato, G; Manjunath, K; Montrella, K; Mueller, B; Nussenblatt, RB; Pizzo, PA, 1992) |
| "Foscarnet and ganciclovir appear to be of similar effectiveness in halting active infection when given as induction therapy and in forestalling progression of disease when given as maintenance therapy in persons with AIDS who have cytomegalovirus (CMV) retinitis." | 3.68 | Therapeutic algorithm for treatment of cytomegalovirus retinitis in persons with AIDS. A roundtable summary. ( Balfour, HH; Drew, WL; Hardy, WD; Heinemann, MH; Polsky, B, 1992) |
| "Foscarnet, administered via a central line, was used for the treatment of 18 episodes of cytomegalovirus (CMV) esophageal ulceration in 15 patients, and in the treatment of 27 episodes of CMV colitis in 22 patients." | 3.68 | Foscarnet in the treatment of cytomegalovirus infection of the esophagus and colon in patients with the acquired immune deficiency syndrome. ( Connolly, GM; Gazzard, BG; Hawkins, DA; Nelson, MR, 1991) |
| "Foscarnet is an investigational antiviral agent that has been used effectively in the treatment of cytomegalovirus (CMV) retinitis in AIDS patients." | 3.68 | Successful foscarnet therapy for cytomegalovirus retinitis in an AIDS patient undergoing hemodialysis: rationale for empiric dosing and plasma level monitoring. ( Gambertoglio, JG; Graziani, AL; Grunwald, JE; MacGregor, RR; Weiss, R, 1991) |
| " Following allogeneic bone marrow transplantation, he developed cytomegalovirus retinitis, which was treated successfully with trisodium phosphonoformate (foscarnet)." | 3.67 | Foscarnet as treatment for cytomegalovirus retinitis following bone marrow transplantation. ( Arthur, C; Ganly, PS; Goldman, JM; Schulenburg, WE, 1988) |
| "Eight patients, 7 renal and 1 combined renal and pancreas allograft recipients with generalized cytomegalovirus (CMV) infection were treated with continuous intravenous foscarnet infusion (0." | 3.67 | Evaluation by immune scanning electron microscopy of foscarnet treatment of cytomegalovirus infection in patients with renal transplants. ( Akesson-Johansson, A; Andersson, J; Brattström, C, 1989) |
| "Ten patients with acquired immunodeficiency syndrome with newly diagnosed cytomegalovirus (CMV) retinitis were treated with an induction regimen of intravenous foscarnet, 60 mg/kg of body weight, administered as a 2-h infusion and repeated every 8 h for 14 days." | 3.67 | Foscarnet treatment of cytomegalovirus retinitis in patients with the acquired immunodeficiency syndrome. ( Jacobson, MA; Mills, J; O'Donnell, JJ, 1989) |
| "Foscarnet was administered as a continuous infusion of 200 mg/kg (prior to 1988) or as an intermittent infusion of 60 mg/kg t." | 2.67 | Treatment of HIV-related cytomegalovirus disease of the gastrointestinal tract with foscarnet. ( Blanshard, C, 1992) |
| "Treatment with Foscarnet may be initially effective, but does not eliminate cytomegalovirus infection." | 2.66 | Cytomegalovirus colitis and oesophageal ulceration in the context of AIDS: clinical manifestations and preliminary report of treatment with Foscarnet (phosphonoformate). ( Barrison, I; Boylston, A; Forster, S; Jeffries, DJ; Pinching, AJ; Thom, S; Unwin, R; Weber, JN, 1987) |
| "Foscarnet has a low solubility and a high degree of ionization at physiologic pH, requiring it to be administered in higher doses and larger volumes." | 2.38 | Approaches to the treatment of cytomegalovirus retinitis: ganciclovir and foscarnet. ( Jacobson, MA; O'Donnell, JJ, 1991) |
| "CMV disease is a major problem in AIDS, though with a different profile from that seen in other immunosuppressed patients." | 2.38 | Cytomegalovirus infection in the acquired immune deficiency syndrome. ( Pinching, AJ, 1989) |
| "How to treat cytomegalovirus infections in patients infected with the human immunodeficiency virus constitutes one of the best examples of the quandaries engendered by these advances, and the topic is reviewed in this first AIDS Commentary update." | 2.38 | Cytomegalovirus infection in patients with AIDS. ( Drew, WL, 1992) |
| " Myelosuppression may be further exacerbated in AIDS patients by such other agents as zidovudine or trimethoprim/sulfamethoxazole, often necessitating dosage reductions or discontinuation of these agents in patients receiving ganciclovir." | 2.38 | Foscarnet sodium. ( Baltz, JK; Minor, JR, 1991) |
| "Acyclovir is a prototype of this improved process." | 2.37 | Promising new antiviral drugs. ( Bryson, YJ, 1988) |
| " An important direction for future clinical research is the development of more effective and less toxic therapy, as well as orally bioavailable drugs for maintenance therapy." | 2.37 | Serious cytomegalovirus disease in the acquired immunodeficiency syndrome (AIDS). Clinical findings, diagnosis, and treatment. ( Jacobson, MA; Mills, J, 1988) |
| "Cytomegalovirus retinitis is probably the result of hematogenous spread of the virus to the retina after systemic reactivation of a latent cytomegalovirus infection." | 2.37 | The diagnosis of cytomegalovirus retinitis. ( Bloom, JN; Palestine, AG, 1988) |
| "Foscarnet was given as a continuous intravenous infusion." | 1.28 | Foscarnet for treatment of cytomegalovirus infections in bone marrow transplant recipients. ( Aschan, J; Ljungman, P; Lönnqvist, B; Ohlman, S; Ringdén, O, 1992) |
| "Foscarnet was discontinued because of adverse events in 3 (3%) of 97 patients, with treatment being stopped in 2 patients because of renal insufficiency and in 1 patient because of an acute neurologic disorder." | 1.28 | Foscarnet induction therapy for cytomegalovirus retinitis in AIDS: comparison of twice-daily and three-times-daily regimens. ( Brancon, C; Caumes, E; Cochereau-Massin, I; Dahan, R; Dohin, E; Gentilini, M; Katlama, C; Robinet, M; Rogeaux, O, 1992) |
| "Eight patients with acquired immunodeficiency syndrome and serious CMV retinitis received 2-h intravenous infusions of foscarnet at a dosage of 60 mg/kg of body weight every 8 h for 14 days." | 1.28 | Pharmacokinetics of intermittently administered intravenous foscarnet in the treatment of acquired immunodeficiency syndrome patients with serious cytomegalovirus retinitis. ( Aweeka, F; Gambertoglio, J; Jacobson, MA; Mills, J, 1989) |
| "Fifty AIDS patients were investigated for human cytomegalovirus (HCMV) viraemia when potentially HCMV-related clinical symptoms or syndromes were observed." | 1.28 | Early virus isolation, early structural antigen detection and DNA amplification by the polymerase chain reaction in polymorphonuclear leukocytes from AIDS patients with human cytomegalovirus viraemia. ( Gaballo, A; Gerna, G; Milanesi, G; Parea, M; Percivalle, E; Zavattoni, M; Zipeto, D, 1991) |
| " Therefore we began treatment with trisodium phosphonoformate (Foscavir) at a dosage of 60 mg/kg body weight per day (3 weeks), continuing with maintenance therapy at 90 mg/kg body weight per day (7 days a week)." | 1.28 | [Therapeutic alternative or 2d choice drug. Trisodium phosphonoformate in cytomegalovirus retinitis]. ( Gümbel, H; Helm, EB; Ohrloff, C; Schalnus, R, 1991) |
| "Foscarnet-induced acute renal failure was defined as a rise in serum creatinine of at least 25% from the basal value." | 1.28 | Foscarnet nephrotoxicity: mechanism, incidence and prevention. ( Baumelou, A; Beaufils, H; Danis, M; Deray, G; Dohin, E; Gentilini, M; Katlama, C; Levaltier, B; Martinez, F; Rozenheim, M, 1989) |
| "Neutropenia was the most frequent and serious side-effect of ganciclovir, 76% patients having neutrophil counts less than 1." | 1.28 | Cytomegalovirus infection in AIDS. Patterns of disease, response to therapy and trends in survival. ( Anderson, S; Beck, EJ; Coker, R; Coleman, D; Harris, JR; Main, J; Migdal, C; Peters, BS; Pinching, AJ, 1991) |
| " Maintenance therapy with DHPG would appear to be necessary to prevent relapse, but the logistics of this are difficult, and the effective dosage of DHPG is as yet uncertain." | 1.27 | Treatment of CMV retinitis in an AIDS patient. ( Acheson, JF; Bradbeer, C; Shah, SM; Spalton, DJ; Thin, RN, 1987) |
| "Foscarnet (FC) is a new antiviral agent which has been recently proposed for the treatment of severe cytomegalovirus (CMV) infections in immunocompromised patients." | 1.27 | Acute renal failure induced by foscarnet: 4 cases. ( Baumelou, A; Cacoub, P; Deray, G; Gentilini, M; Jacobs, C; Le Hoang, P; Rousselie, R; Rozenbaum, W; Soubrie, C, 1988) |
| " The dosage of Foscarnet was increased during the study." | 1.27 | Clinical experiences with phosphonoformate (foscarnet) treatment of viral diseases following renal transplantation. ( Ahlmén, J; Brynger, H; Lycke, E; Wijnween, AC, 1985) |
| " Adverse effects, such as decreased haemoglobin, decreased renal function and increased serum calcium, were observed in a few patients only." | 1.27 | Pharmacokinetics, safety and preliminary clinical experiences using foscarnet in the treatment of cytomegalovirus infections in bone marrow and renal transplant recipients. ( Ahlmén, J; Klintmalm, G; Lernestedt, JO; Lönnqvist, B; Paulin, T; Ringdén, O; Wahren, B, 1986) |
| "Foscarnet was administered to eight AIDS patients for suspected cytomegalovirus (CMV) pneumonitis as a continuous intravenous infusion for a minimum of 8 days." | 1.27 | Treatment of cytomegalovirus pneumonitis with foscarnet (trisodium phosphonoformate) in patients with AIDS. ( Anderson, MG; Chanas, AC; Ellis, ME; Farthing, C; Gazzard, BG, 1987) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 44 (34.92) | 18.7374 |
| 1990's | 82 (65.08) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Radsak, K | 1 |
| Wiegandt, H | 1 |
| Burns, WH | 1 |
| Wingard, JR | 1 |
| Sandford, GR | 1 |
| Bender, WJ | 1 |
| Saral, R | 1 |
| Lucia, HL | 1 |
| Griffith, BP | 1 |
| Hsiung, GD | 1 |
| Snoeck, R | 2 |
| Andrei, G | 1 |
| De Clercq, E | 2 |
| Timmerman, JJ | 1 |
| Beersma, MF | 1 |
| van Gijlswijk-Janssen, DJ | 1 |
| van Es, LA | 1 |
| van der Woude, FJ | 1 |
| Daha, MR | 1 |
| Healy, B | 1 |
| Hirsch, MS | 1 |
| Masur, H | 1 |
| Heinemann, MH | 2 |
| Polis, MA | 3 |
| Jacobson, MA | 12 |
| Jabs, DA | 1 |
| Butler, KM | 1 |
| De Smet, MD | 2 |
| Husson, RN | 1 |
| Mueller, B | 1 |
| Manjunath, K | 1 |
| Montrella, K | 1 |
| Lovato, G | 1 |
| Jarosinski, P | 1 |
| Nussenblatt, RB | 1 |
| Pizzo, PA | 1 |
| Salit, IE | 1 |
| Evans, JK | 1 |
| Scoular, A | 1 |
| Miller, RF | 1 |
| Drew, WL | 3 |
| Nicoli, F | 1 |
| Dhiver, C | 1 |
| Chave, B | 1 |
| Poizot-Martin, I | 1 |
| Gastaut, JA | 1 |
| Gastaut, JL | 1 |
| Cerrina, J | 1 |
| Le Roy Ladurie, F | 1 |
| Wilson, RJ | 1 |
| Skolnik, PR | 1 |
| Deray, G | 4 |
| Katlama, C | 5 |
| Jacobs, C | 2 |
| Bachman, DM | 1 |
| Peters, M | 1 |
| Timm, U | 1 |
| Schürmann, D | 1 |
| Pohle, HD | 1 |
| Ruf, B | 1 |
| Dohin, E | 3 |
| Caumes, E | 1 |
| Cochereau-Massin, I | 1 |
| Brancon, C | 1 |
| Robinet, M | 2 |
| Rogeaux, O | 2 |
| Dahan, R | 1 |
| Gentilini, M | 3 |
| Blanshard, C | 1 |
| Balfour, HH | 1 |
| Hardy, WD | 1 |
| Polsky, B | 1 |
| Manji, H | 1 |
| Malin, A | 1 |
| Connolly, S | 1 |
| Evans, LM | 1 |
| Grossman, ME | 1 |
| Cotte, L | 1 |
| Langlois, M | 1 |
| Trepo, C | 1 |
| Aschan, J | 2 |
| Ringdén, O | 6 |
| Ljungman, P | 1 |
| Lönnqvist, B | 6 |
| Ohlman, S | 1 |
| Reusser, P | 1 |
| Gambertoglio, JG | 2 |
| Lilleby, K | 1 |
| Meyers, JD | 3 |
| Reddy, MM | 1 |
| Grieco, MH | 1 |
| McKinley, GF | 1 |
| Causey, DM | 1 |
| van der Horst, CM | 1 |
| Parenti, DM | 1 |
| Hooton, TM | 1 |
| Davis, RB | 1 |
| Levinson, ML | 1 |
| Jacobson, PA | 1 |
| Moyle, G | 1 |
| Harman, C | 1 |
| Mitchell, S | 1 |
| Mathalone, B | 1 |
| Gazzard, BG | 5 |
| Bedos, JP | 1 |
| Wolf, M | 1 |
| Vachon, F | 1 |
| Morris, DJ | 1 |
| Wood, CA | 1 |
| Enting, R | 1 |
| de Gans, J | 1 |
| Reiss, P | 2 |
| Jansen, C | 1 |
| Portegies, P | 1 |
| Feinberg, J | 1 |
| O'Donnell, JJ | 5 |
| Whitmore, PV | 1 |
| Miner, RD | 1 |
| Parenti, D | 1 |
| Petersen, EA | 1 |
| Reed, EC | 2 |
| Nelson, MR | 2 |
| Connolly, GM | 2 |
| Hawkins, DA | 2 |
| Charpentier, B | 1 |
| Drobyski, WR | 2 |
| Knox, KK | 2 |
| Carrigan, DR | 2 |
| Ash, RC | 1 |
| MacGregor, RR | 1 |
| Graziani, AL | 1 |
| Weiss, R | 1 |
| Grunwald, JE | 1 |
| Palestine, AG | 2 |
| Baird, BF | 1 |
| Falloon, J | 1 |
| Kovacs, JA | 1 |
| Davey, RT | 1 |
| Zurlo, JJ | 1 |
| Zunich, KM | 1 |
| Davis, M | 1 |
| Marwick, C | 1 |
| Moeland, A | 1 |
| Bruun, JN | 1 |
| Smyth, RL | 1 |
| Scott, JP | 1 |
| Borysiewicz, LK | 1 |
| Sharples, LD | 1 |
| Stewart, S | 1 |
| Wreghitt, TG | 1 |
| Gray, JJ | 1 |
| Higenbottam, TW | 1 |
| Wallwork, J | 1 |
| Nightingale, SL | 1 |
| Minor, JR | 2 |
| Peters, BS | 2 |
| Beck, EJ | 1 |
| Anderson, S | 1 |
| Coleman, D | 1 |
| Coker, R | 1 |
| Main, J | 1 |
| Migdal, C | 2 |
| Harris, JR | 2 |
| Pinching, AJ | 4 |
| Lowenstein, W | 1 |
| Fadlallah, JP | 1 |
| Roudière, L | 1 |
| Deneux, C | 1 |
| Haas, C | 1 |
| Durand, H | 1 |
| Harb, GE | 1 |
| Bacchetti, P | 1 |
| Gerna, G | 1 |
| Zipeto, D | 1 |
| Parea, M | 1 |
| Percivalle, E | 1 |
| Zavattoni, M | 1 |
| Gaballo, A | 1 |
| Milanesi, G | 1 |
| Gümbel, H | 1 |
| Ohrloff, C | 1 |
| Schalnus, R | 1 |
| Helm, EB | 1 |
| Neyts, J | 1 |
| Schols, D | 1 |
| Himpens, B | 1 |
| Jenkins, RE | 1 |
| Barter, G | 1 |
| Hawkins, D | 1 |
| Coker, RJ | 1 |
| Tomlinson, D | 1 |
| Horner, P | 1 |
| Griffiths, PD | 1 |
| Chrisp, P | 1 |
| Clissold, SP | 1 |
| Paul, AA | 1 |
| Leeper, HF | 1 |
| Friberg, TR | 1 |
| Söderlund, C | 1 |
| Bratt, G | 1 |
| Grützmeier, S | 1 |
| Rieger, A | 1 |
| Sandström, E | 1 |
| Sjunnesson, M | 1 |
| Henderly, DE | 1 |
| Jampol, LM | 1 |
| Baltz, JK | 1 |
| Van Der Pijl, JW | 1 |
| Frissen, PH | 1 |
| Hulsebosch, HJ | 1 |
| Van Den Tweel, JG | 1 |
| Lange, JM | 1 |
| Danner, SA | 1 |
| Youle, M | 1 |
| Chanas, A | 2 |
| Gazzard, B | 1 |
| Leport, C | 1 |
| Salmon, D | 1 |
| Fanning, MM | 2 |
| Read, SE | 2 |
| Benson, M | 1 |
| Vas, S | 1 |
| Rachlis, A | 2 |
| Kozousek, V | 1 |
| Mortimer, C | 1 |
| Harvey, P | 1 |
| Schwartz, C | 1 |
| Chew, E | 2 |
| Farese, RV | 1 |
| Schambelan, M | 1 |
| Hollander, H | 1 |
| Stringari, S | 1 |
| Cotton, P | 1 |
| Bryson, YJ | 1 |
| Sakuma, T | 1 |
| Azuma, M | 1 |
| Chiba, S | 1 |
| Lehoang, P | 1 |
| Girard, B | 1 |
| Marcel, P | 1 |
| Zazoun, L | 1 |
| Matheron, S | 1 |
| Rozenbaum, W | 2 |
| Morer, I | 1 |
| Lernestedt, JO | 6 |
| Mills, J | 5 |
| Aweeka, F | 2 |
| Gambertoglio, J | 2 |
| Martinez, F | 1 |
| Levaltier, B | 1 |
| Beaufils, H | 1 |
| Danis, M | 1 |
| Rozenheim, M | 1 |
| Baumelou, A | 2 |
| Sundberg, B | 1 |
| Andersson, J | 1 |
| Akesson-Johansson, A | 3 |
| Brattström, C | 1 |
| Nyberg, G | 1 |
| Svalander, C | 1 |
| Blohmé, I | 1 |
| Persson, H | 1 |
| Wood, G | 1 |
| Whitby, M | 1 |
| Hogan, P | 1 |
| Frazer, I | 1 |
| Acheson, JF | 1 |
| Shah, SM | 1 |
| Spalton, DJ | 1 |
| Bradbeer, C | 1 |
| Thin, RN | 1 |
| Debs, RJ | 1 |
| Montgomery, AB | 1 |
| Brunette, EN | 1 |
| DeBruin, M | 1 |
| Shanley, JD | 1 |
| Walmsley, SL | 1 |
| Vellend, H | 1 |
| Salit, I | 1 |
| Cacoub, P | 1 |
| Le Hoang, P | 2 |
| Soubrie, C | 1 |
| Rousselie, R | 1 |
| Wahren, B | 4 |
| Crowe, S | 1 |
| Levy, J | 1 |
| McManus, N | 1 |
| Rush, J | 1 |
| Miller, RG | 1 |
| Greco, C | 1 |
| Gonzales, MF | 1 |
| Bloom, JN | 1 |
| Ganly, PS | 1 |
| Arthur, C | 1 |
| Goldman, JM | 2 |
| Schulenburg, WE | 2 |
| Wyngaarden, JB | 1 |
| Michon, C | 1 |
| Girard, PM | 1 |
| Ngovan, P | 1 |
| Simonpoli, AM | 1 |
| Apperley, JF | 1 |
| Marcus, RE | 1 |
| Wardle, DG | 1 |
| Gravett, PJ | 1 |
| Wilczek, H | 1 |
| Gahrton, G | 2 |
| Heley, A | 1 |
| Klintmalm, G | 2 |
| Oberg, B | 1 |
| Lundgren, G | 1 |
| Robert, KH | 1 |
| Groth, CG | 1 |
| Singer, DR | 1 |
| Fallon, TJ | 1 |
| Williams, G | 1 |
| Cohen, J | 1 |
| Ahlmén, J | 2 |
| Wijnween, AC | 1 |
| Brynger, H | 1 |
| Lycke, E | 1 |
| Paulin, T | 1 |
| Larson, A | 1 |
| Frödin, L | 2 |
| Tufveson, G | 2 |
| Larsson, E | 1 |
| Källander, CF | 2 |
| Gronowitz, JS | 2 |
| Larsson, A | 1 |
| Claesson, K | 1 |
| Sjöberg, O | 1 |
| Brochard, L | 1 |
| Salmeron, S | 1 |
| Herve, P | 1 |
| Petitpretz, P | 1 |
| Boissonnas, A | 1 |
| Simonneau, G | 1 |
| Duroux, P | 1 |
| Weber, JN | 1 |
| Thom, S | 1 |
| Barrison, I | 1 |
| Unwin, R | 1 |
| Forster, S | 1 |
| Jeffries, DJ | 1 |
| Boylston, A | 1 |
| Gluckman, E | 1 |
| Keable, H | 1 |
| Meletis, J | 1 |
| Bombail, D | 1 |
| Jolivet, I | 1 |
| Huart, JJ | 1 |
| Nebout, T | 1 |
| Cavazzana, M | 1 |
| De Castro, H | 1 |
| Farthing, C | 1 |
| Anderson, MG | 1 |
| Ellis, ME | 1 |
| Chanas, AC | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Foscarnet-Ganciclovir CMV Retinitis Trial[NCT00000136] | Phase 3 | 234 participants (Actual) | Interventional | 1990-03-31 | Completed | ||
| Studies of the Ocular Complications of AIDS (SOCA) CMV Retinitis Trial: Foscarnet-Ganciclovir Component[NCT00000665] | 240 participants | Interventional | Completed | ||||
| A Phase II Randomized Controlled Trial of Immediate Versus Delayed Foscarnet Therapy in AIDS Patients With Non-Immediately Sight-Threatening CMV Retinitis Who Cannot Be Treated With Ganciclovir Due to Myelosuppression[NCT00000697] | Phase 2 | 0 participants (Actual) | Interventional | Withdrawn | |||
| A Phase II Dose-Ranging, Open-Labelled Trial of Foscarnet Salvage Therapy for AIDS Patients With Sight-Threatening CMV Retinitis Who Cannot Be Treated With Ganciclovir Due To Myelosuppression or Treatment Failure[NCT00000691] | Phase 2 | 156 participants | Interventional | Completed | |||
| Foscarnet Treatment of Serious CMV Retinitis Infection in Patients With Acquired Immunodeficiency Syndrome[NCT00000726] | Phase 1 | 53 participants | Interventional | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT00000136)
Timeframe: All patients enrolled will be followed until a common study closing date, which was chosen to provide a minimum of 1 year of follow-up for all patients enrolled in the trial.
| Intervention | participants (Number) |
|---|---|
| Foscarnet | 107 |
| Ganciclovir | 127 |
26 reviews available for phosphonoacetic acid and Cytomegalovirus Infections
| Article | Year |
|---|---|
Characteristics of cytomegalovirus retinitis in patients with acquired immunodeficiency syndrome.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Cytomegalovirus Infections; Eye Infections, Vi | 1992 |
Maintenance therapy for cytomegalovirus retinitis in patients with acquired immunodeficiency syndrome: foscarnet.
Topics: Antiviral Agents; Cytomegalovirus Infections; Drug Therapy, Combination; Eye Infections, Viral; Fosc | 1992 |
Cytomegalovirus infection in patients with AIDS.
Topics: Acquired Immunodeficiency Syndrome; Chorioretinitis; Cytomegalovirus Infections; Encephalitis; Fosca | 1992 |
[Cytomegalovirus infection in patients after lung transplantation].
Topics: Acyclovir; Antiviral Agents; Blood Transfusion; Cytomegalovirus; Cytomegalovirus Infections; Foscarn | 1992 |
Cytomegalovirus retinitis in AIDS.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Cytomegalovirus Infections; Diagnosis, Differe | 1992 |
Combined and alternating ganciclovir and foscarnet in acute and maintenance therapy of human immunodeficiency virus-related cytomegalovirus encephalitis refractory to ganciclovir alone. A case report and review of the literature.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antiviral Agents; Cytomegalovirus; Cytomegalovirus Infect | 1992 |
Foscarnet and ganciclovir in the treatment of cytomegalovirus retinitis.
Topics: Cytomegalovirus Infections; Drug Therapy, Combination; Foscarnet; Ganciclovir; Humans; Phosphonoacet | 1992 |
Foscarnet-induced penile ulcer.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antiviral Agents; Cytomegalovirus Infections; Foscarnet; | 1992 |
Treatment and prophylaxis of cytomegalovirus disease.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Cytomegalovirus Infections; Foscarnet; Gancicl | 1992 |
Extrapulmonary cytomegalovirus disease in transplant patients.
Topics: Antiviral Agents; Bone Marrow Transplantation; Cytomegalovirus Infections; Foscarnet; Ganciclovir; H | 1991 |
Treatment of cytomegalovirus pneumonia in transplant patients.
Topics: Cytomegalovirus Infections; Drug Therapy, Combination; Foscarnet; Ganciclovir; Humans; Immunization, | 1991 |
[Cytomegalovirus infections in transplant patients].
Topics: Antiviral Agents; Cytomegalovirus Infections; Foscarnet; Ganciclovir; Humans; Immune Tolerance; Inci | 1991 |
[Treatment of herpesvirus infections].
Topics: Acyclovir; Antiviral Agents; Cytomegalovirus Infections; Drug Resistance, Microbial; Foscarnet; Ganc | 1991 |
Advances in the prevention and treatment of cytomegalovirus infection in hospital patients.
Topics: Antibodies, Monoclonal; Antiviral Agents; Bronchoalveolar Lavage Fluid; Cross Infection; Cytomegalov | 1991 |
Foscarnet. A review of its antiviral activity, pharmacokinetic properties and therapeutic use in immunocompromised patients with cytomegalovirus retinitis.
Topics: Acquired Immunodeficiency Syndrome; Anemia; Animals; Antiviral Agents; Cytomegalovirus; Cytomegalovi | 1991 |
Approaches to the treatment of cytomegalovirus retinitis: ganciclovir and foscarnet.
Topics: Antiviral Agents; Cytomegalovirus Infections; Drug Therapy, Combination; Eye Infections, Viral; Fosc | 1991 |
Diagnosis and treatment of cytomegalovirus retinitis.
Topics: Antiviral Agents; Cytomegalovirus Infections; Diagnosis, Differential; Eye Infections, Viral; Foscar | 1991 |
Foscarnet sodium.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Cytomegalovirus Infections; Eye Infections, Vi | 1991 |
Treatment of cytomegalovirus infection.
Topics: Acyclovir; Clinical Trials as Topic; Cytomegalovirus Infections; Foscarnet; Ganciclovir; Humans; Imm | 1987 |
Promising new antiviral drugs.
Topics: Acyclovir; Animals; Antiviral Agents; Bromodeoxyuridine; Cytomegalovirus Infections; Foscarnet; Ganc | 1988 |
Cotton-wool spots and cytomegalovirus retinitis in AIDS.
Topics: Acquired Immunodeficiency Syndrome; Acyclovir; Cytomegalovirus Infections; Diabetic Retinopathy; Dia | 1989 |
Cytomegalovirus infection in the acquired immune deficiency syndrome.
Topics: Acquired Immunodeficiency Syndrome; Acyclovir; Addison Disease; Antiviral Agents; Colitis; Cytomegal | 1989 |
Serious cytomegalovirus disease in the acquired immunodeficiency syndrome (AIDS). Clinical findings, diagnosis, and treatment.
Topics: Acquired Immunodeficiency Syndrome; Acyclovir; Antiviral Agents; Cytomegalovirus Infections; Foscarn | 1988 |
Management of cytomegalovirus infection.
Topics: Acyclovir; Antiviral Agents; Cytomegalovirus Infections; Foscarnet; Ganciclovir; Humans; Immunizatio | 1988 |
The diagnosis of cytomegalovirus retinitis.
Topics: Acquired Immunodeficiency Syndrome; Acyclovir; Antiviral Agents; Cytomegalovirus Infections; Diagnos | 1988 |
[Treatment of cytomegalovirus infections in immunosuppressed patients].
Topics: Acquired Immunodeficiency Syndrome; Acyclovir; Antiviral Agents; Cytomegalovirus Infections; Foscarn | 1988 |
16 trials available for phosphonoacetic acid and Cytomegalovirus Infections
| Article | Year |
|---|---|
The treatment of cytomegalovirus in AIDS--more than meets the eye.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Cytomegalovirus Infections; Drug Therapy, Comb | 1992 |
Design of a randomized controlled trial of foscarnet in patients with cytomegalovirus retinitis associated with acquired immunodeficiency syndrome.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antiviral Agents; Cytomegalovirus Infections; Eye Infecti | 1992 |
Studies of ocular complications of AIDS Foscarnet-Ganciclovir Cytomegalovirus Retinitis Trial: 1. Rationale, design, and methods. AIDS Clinical Trials Group (ACTG).
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Clinical Trials as Topic; Cytomegalovirus Infe | 1992 |
Studies of ocular complications of AIDS Foscarnet-Ganciclovir Cytomegalovirus Retinitis Trial: 1. Rationale, design, and methods. AIDS Clinical Trials Group (ACTG).
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Clinical Trials as Topic; Cytomegalovirus Infe | 1992 |
Studies of ocular complications of AIDS Foscarnet-Ganciclovir Cytomegalovirus Retinitis Trial: 1. Rationale, design, and methods. AIDS Clinical Trials Group (ACTG).
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Clinical Trials as Topic; Cytomegalovirus Infe | 1992 |
Studies of ocular complications of AIDS Foscarnet-Ganciclovir Cytomegalovirus Retinitis Trial: 1. Rationale, design, and methods. AIDS Clinical Trials Group (ACTG).
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Clinical Trials as Topic; Cytomegalovirus Infe | 1992 |
Treatment of HIV-related cytomegalovirus disease of the gastrointestinal tract with foscarnet.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Cytomegalovirus Infections; Female; Foscarnet; | 1992 |
Phase I-II trial of foscarnet for prevention of cytomegalovirus infection in autologous and allogeneic marrow transplant recipients.
Topics: Adolescent; Adult; Antiviral Agents; Bone Marrow Transplantation; Cytomegalovirus Infections; Drug E | 1992 |
Effect of foscarnet therapy on human immunodeficiency virus p24 antigen levels in AIDS patients with cytomegalovirus retinitis.
Topics: Acquired Immunodeficiency Syndrome; Adult; Cytomegalovirus Infections; Dose-Response Relationship, D | 1992 |
Foscarnet and Ganciclovir in the treatment of CMV retinitis in AIDS patients: a randomised comparison.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Cytomegalovirus Infections; Foscarnet; Gancicl | 1992 |
Mortality in patients with the acquired immunodeficiency syndrome treated with either foscarnet or ganciclovir for cytomegalovirus retinitis.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antiviral Agents; CD4-Positive T-Lymphocytes; Cytomegalov | 1992 |
Mortality in patients with the acquired immunodeficiency syndrome treated with either foscarnet or ganciclovir for cytomegalovirus retinitis.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antiviral Agents; CD4-Positive T-Lymphocytes; Cytomegalov | 1992 |
Mortality in patients with the acquired immunodeficiency syndrome treated with either foscarnet or ganciclovir for cytomegalovirus retinitis.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antiviral Agents; CD4-Positive T-Lymphocytes; Cytomegalov | 1992 |
Mortality in patients with the acquired immunodeficiency syndrome treated with either foscarnet or ganciclovir for cytomegalovirus retinitis.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antiviral Agents; CD4-Positive T-Lymphocytes; Cytomegalov | 1992 |
AIDS file.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Cytomegalovirus Infections; Foscarnet; Gancicl | 1991 |
A randomized, controlled trial of foscarnet in the treatment of cytomegalovirus retinitis in patients with AIDS.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antiviral Agents; Cytomegalovirus Infections; Eye Infecti | 1991 |
Foscarnet versus ganciclovir in the management of cytomegalovirus disease in patients with AIDS.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Cytomegalovirus Infections; Foscarnet; Gancicl | 1991 |
Treatment of acquired immune deficiency syndrome (AIDS)-related pneumonitis with foscarnet: a double-blind placebo controlled study.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Cytomegalovirus; Cytomegalovirus Infections; D | 1990 |
Treatment of cytomegalovirus infection.
Topics: Acyclovir; Clinical Trials as Topic; Cytomegalovirus Infections; Foscarnet; Ganciclovir; Humans; Imm | 1987 |
Sensitivity of cytomegalovirus to intravenous foscarnet treatment.
Topics: Antiviral Agents; Bone Marrow Transplantation; Cytomegalovirus; Cytomegalovirus Infections; Female; | 1986 |
From the National Institutes of Health. Progress in AIDS research.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Clinical Trials as Topic; Cytomegalovirus Infe | 1988 |
Cytomegalovirus colitis and oesophageal ulceration in the context of AIDS: clinical manifestations and preliminary report of treatment with Foscarnet (phosphonoformate).
Topics: Acquired Immunodeficiency Syndrome; Adult; Clinical Trials as Topic; Colitis; Cytomegalovirus Infect | 1987 |
85 other studies available for phosphonoacetic acid and Cytomegalovirus Infections
| Article | Year |
|---|---|
Glycosphingolipid synthesis in human fibroblasts infected by cytomegalovirus.
Topics: Cell Differentiation; Cells, Cultured; Cytomegalovirus Infections; Glycosphingolipids; Humans; Isoel | 1984 |
Acyclovir in mouse cytomegalovirus infections.
Topics: Acyclovir; Animals; Antiviral Agents; Cytomegalovirus; Cytomegalovirus Infections; Drug Resistance; | 1982 |
Effect of acyclovir and phosphonoformate on cytomegalovirus infection in guinea pigs.
Topics: Acyclovir; Animals; Antiviral Agents; Cytomegalovirus Infections; Disease Models, Animal; Foscarnet; | 1984 |
Patterns of resistance and sensitivity to antiviral compounds of drug-resistant strains of human cytomegalovirus selected in vitro.
Topics: Acyclovir; Adenine; Antiviral Agents; Cells, Cultured; Cidofovir; Cytarabine; Cytomegalovirus; Cytom | 1996 |
Differential effects of cytomegalovirus infection on complement synthesis by human mesangial cells.
Topics: Blotting, Northern; Cells, Cultured; Complement C2; Complement C4; Complement Factor B; Complement F | 1997 |
From the National Institutes of Health.
Topics: Acquired Immunodeficiency Syndrome; Anti-Inflammatory Agents, Non-Steroidal; Antiviral Agents; Arthr | 1992 |
Foscarnet.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Cytomegalovirus Infections; Eye Infections, Vi | 1992 |
Didanosine and foscarnet marketed for use by patients with AIDS.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Cytomegalovirus Infections; Didanosine; Foscar | 1992 |
Clinical implications of herpesvirus infections in patients with AIDS. Introduction.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Cytomegalovirus Infections; Eye Infections, Vi | 1992 |
Treatment of cytomegalovirus retinitis--1992.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Cytomegalovirus Infections; Eye Infections, Vi | 1992 |
Treatment of aggressive cytomegalovirus retinitis with ganciclovir in combination with foscarnet in a child infected with human immunodeficiency virus.
Topics: Antiviral Agents; Child, Preschool; Cytomegalovirus Infections; Drug Therapy, Combination; Female; F | 1992 |
Why was treatment of cytomegalovirus retinitis randomized?
Topics: Antiviral Agents; Cytomegalovirus Infections; Eye Infections, Viral; Foscarnet; Ganciclovir; Humans; | 1992 |
Cytomegalovirus and AIDS.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antiviral Agents; Cytomegalovirus Infections; Foscarnet; | 1992 |
[Regressive diffuse leukoencephalitis under foscarnet in an AIDS infected patient].
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Cytomegalovirus Infections; Encephalitis; Fosc | 1992 |
Treatment of CMV retinitis.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Cytomegalovirus Infections; Drug Therapy, Comb | 1992 |
Treatment of CMV retinitis.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Cytomegalovirus Infections; Foscarnet; Gancicl | 1992 |
Treatment of CMV retinitis.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Cytomegalovirus Infections; Foscarnet; Gancicl | 1992 |
Foscarnet induction therapy for cytomegalovirus retinitis in AIDS: comparison of twice-daily and three-times-daily regimens.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antiviral Agents; Cytomegalovirus Infections; Drug Admini | 1992 |
Therapeutic algorithm for treatment of cytomegalovirus retinitis in persons with AIDS. A roundtable summary.
Topics: Acquired Immunodeficiency Syndrome; Adult; Algorithms; Cytomegalovirus Infections; Foscarnet; Gancic | 1992 |
CMV polyradiculopathy in AIDS--suggestions for new strategies in treatment.
Topics: Acquired Immunodeficiency Syndrome; Adult; Cytomegalovirus Infections; Foscarnet; Humans; Male; Nerv | 1992 |
Herpes simplex virus infection during foscarnet therapy.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antiviral Agents; Cytomegalovirus Infections; Foscarnet; | 1992 |
Foscarnet for treatment of cytomegalovirus infections in bone marrow transplant recipients.
Topics: Adolescent; Adult; Antiviral Agents; Bone Marrow Transplantation; Calcium; Child; Child, Preschool; | 1992 |
[Myelo-meningoradiculitis secondary to cytomegalovirus infection in a non immunocompromised patient. Treatment with foscarnet].
Topics: Adolescent; Antiviral Agents; Bone Marrow Diseases; Cytomegalovirus Infections; Foscarnet; Humans; M | 1992 |
Treatment of CMV retinitis.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Cytomegalovirus Infections; Eye Infections, Vi | 1992 |
Foscarnet for CMV retinitis.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Cytomegalovirus Infections; Foscarnet; Gancicl | 1992 |
Ganciclovir/foscarnet for cytomegalovirus meningoencephalitis in AIDS.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antiviral Agents; Cytomegalovirus Infections; Drug Therap | 1992 |
Foscarnet therapy for ganciclovir-resistant cytomegalovirus retinitis in patients with AIDS.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antiviral Agents; Cytomegalovirus; Cytomegalovirus Infect | 1991 |
Foscarnet in the treatment of cytomegalovirus infection of the esophagus and colon in patients with the acquired immune deficiency syndrome.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antiviral Agents; Colitis; Cytomegalovirus Infections; Es | 1991 |
Foscarnet therapy of ganciclovir-resistant cytomegalovirus in marrow transplantation.
Topics: Adult; Antiviral Agents; Bone Marrow Transplantation; Cytomegalovirus; Cytomegalovirus Infections; D | 1991 |
Successful foscarnet therapy for cytomegalovirus retinitis in an AIDS patient undergoing hemodialysis: rationale for empiric dosing and plasma level monitoring.
Topics: Acquired Immunodeficiency Syndrome; Acute Kidney Injury; Adult; Antiviral Agents; Cytomegalovirus In | 1991 |
National Eye Institute issues clinical alert about CMV retinitis in AIDS.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Cytomegalovirus Infections; Eye Infections, Vi | 1991 |
Foscarnet approved for cytomegalovirus retinitis.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Cytomegalovirus Infections; Foscarnet; Humans; | 1991 |
Cytomegalovirus infection in heart-lung transplant recipients: risk factors, clinical associations, and response to treatment.
Topics: Adolescent; Adult; Antibodies, Viral; Bacterial Infections; Child; Cytomegalovirus; Cytomegalovirus | 1991 |
From the Food and Drug Administration.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Cytomegalovirus Infections; Eye Infections, Vi | 1991 |
Cytomegalovirus infection in AIDS. Patterns of disease, response to therapy and trends in survival.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Colitis; Cytomegalovirus Infections; Female; F | 1991 |
[Prevention of genital erosions during treatments with foscarnet of cytomegalovirus infections in AIDS].
Topics: Acquired Immunodeficiency Syndrome; Adult; Antiviral Agents; Cytomegalovirus Infections; Foscarnet; | 1991 |
Survival of patients with AIDS and cytomegalovirus disease treated with ganciclovir or foscarnet.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antiviral Agents; Cytomegalovirus Infections; Female; Fos | 1991 |
Early virus isolation, early structural antigen detection and DNA amplification by the polymerase chain reaction in polymorphonuclear leukocytes from AIDS patients with human cytomegalovirus viraemia.
Topics: Acquired Immunodeficiency Syndrome; Antigens, Viral; Antiviral Agents; Cytomegalovirus; Cytomegalovi | 1991 |
[Therapeutic alternative or 2d choice drug. Trisodium phosphonoformate in cytomegalovirus retinitis].
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Chorioretinitis; Cytomegalovirus Infections; D | 1991 |
Sensitive, reproducible and convenient fluorometric assay for the in vitro evaluation of anti-cytomegalovirus agents.
Topics: Acyclovir; Antiviral Agents; Cidofovir; Cytomegalovirus; Cytomegalovirus Infections; Cytosine; Ester | 1991 |
Thromboembolic disease in AIDS is associated with cytomegalovirus disease.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antiviral Agents; Cytomegalovirus Infections; Foscarnet; | 1991 |
Cytomegalovirus isolate resistant to ganciclovir and foscarnet from a marrow transplant patient.
Topics: Adult; Antiviral Agents; Bone Transplantation; Cytomegalovirus; Cytomegalovirus Infections; Drug Res | 1991 |
Simultaneous treatment of cytomegalovirus retinitis with ganciclovir and foscarnet.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antiviral Agents; Cytomegalovirus Infections; Eye Infecti | 1991 |
Treatment of cytomegalovirus retinitis with ganciclovir and foscarnet.
Topics: Adult; Cytomegalovirus Infections; Drug Combinations; Foscarnet; Ganciclovir; HIV Seropositivity; Hu | 1991 |
Seeing the way forward for treatment of CMV retinitis.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Clinical Trials as Topic; Cytomegalovirus Infe | 1991 |
CMV retinitis and the use of FK 506.
Topics: Acyclovir; Antiviral Agents; Cytomegalovirus Infections; Foscarnet; Humans; Immunosuppression Therap | 1991 |
[Cytomegalovirus ileocolitis in patients with HIV infection is a treatable cause of severe abdominal problems].
Topics: Acquired Immunodeficiency Syndrome; Adult; Antiviral Agents; Cecum; Crohn Disease; Cytomegalovirus I | 1991 |
Foscarnet and penile ulceration.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Cytomegalovirus Infections; Foscarnet; Herpes | 1990 |
Penile ulcerations with foscarnet.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antiviral Agents; Cytomegalovirus Infections; Foscarnet; | 1990 |
[Treatment of Cytomegalovirus infection].
Topics: Antiviral Agents; Cytomegalovirus Infections; Foscarnet; Ganciclovir; Humans; Immune Tolerance; Phos | 1990 |
Foscarnet therapy of cytomegalovirus retinitis in AIDS.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Cytomegalovirus Infections; Foscarnet; Humans; | 1990 |
Nephrogenic diabetes insipidus associated with foscarnet treatment of cytomegalovirus retinitis.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antiviral Agents; Cytomegalovirus Infections; Diabetes In | 1990 |
Fixed drug eruption due to foscarnet.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antiviral Agents; Cytomegalovirus Infections; Drug Erupti | 1990 |
Prevention of foscarnet nephrotoxicity.
Topics: Adult; Antiviral Agents; Cytomegalovirus Infections; Eye Infections, Viral; Female; Fluid Therapy; F | 1990 |
Wider access provided to AIDS drugs with actions against HIV, CMV infections.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Cytomegalovirus Infections; Foscarnet; HIV Inf | 1990 |
[Chemotherapy of cytomegalovirus infections].
Topics: Acyclovir; Adenine; Cytomegalovirus Infections; Foscarnet; Ganciclovir; Humans; Organophosphonates; | 1989 |
[Diagnosis and treatment of cytomegalovirus infections].
Topics: Acyclovir; Antigens, Viral; Cytomegalovirus; Cytomegalovirus Infections; DNA, Viral; Female; Foscarn | 1989 |
Foscarnet in the treatment of cytomegalovirus retinitis in acquired immune deficiency syndrome.
Topics: Acquired Immunodeficiency Syndrome; Adult; Creatine; Cytomegalovirus Infections; Drug Therapy, Combi | 1989 |
Foscarnet treatment of cytomegalovirus retinitis in patients with the acquired immunodeficiency syndrome.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antiviral Agents; Calcium; Cytomegalovirus Infections; Fo | 1989 |
Pharmacokinetics of intermittently administered intravenous foscarnet in the treatment of acquired immunodeficiency syndrome patients with serious cytomegalovirus retinitis.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antiviral Agents; Cytomegalovirus Infections; Foscarnet; | 1989 |
Foscarnet nephrotoxicity: mechanism, incidence and prevention.
Topics: Acute Kidney Injury; Adult; Aged; Cohort Studies; Creatinine; Cytomegalovirus Infections; Fluid Ther | 1989 |
Foscarnet prophylaxis in marrow transplant recipients.
Topics: Bone Marrow Transplantation; Cytomegalovirus; Cytomegalovirus Infections; Foscarnet; Humans; Nucleic | 1989 |
Evaluation by immune scanning electron microscopy of foscarnet treatment of cytomegalovirus infection in patients with renal transplants.
Topics: Adolescent; Adult; Aged; Child; Child, Preschool; Cytomegalovirus; Cytomegalovirus Infections; Drug | 1989 |
Tubulointerstitial nephritis caused by the antiviral agent foscarnet.
Topics: Adult; Antiviral Agents; Cytomegalovirus Infections; Female; Foscarnet; Humans; Kidney Transplantati | 1989 |
Foscarnet infusion at home.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antiviral Agents; Cytomegalovirus Infections; Drug Admini | 1989 |
Treatment of CMV retinitis in an AIDS patient.
Topics: Acquired Immunodeficiency Syndrome; Acyclovir; Antiviral Agents; Cytomegalovirus Infections; Foscarn | 1987 |
Aerosol administration of antiviral agents to treat lung infection due to murine cytomegalovirus.
Topics: Acyclovir; Administration, Oral; Aerosols; Animals; Antiviral Agents; Cytomegalovirus Infections; Di | 1988 |
Treatment of cytomegalovirus retinitis with trisodium phosphonoformate hexahydrate (Foscarnet).
Topics: Acquired Immunodeficiency Syndrome; Adult; Antiviral Agents; Cytomegalovirus Infections; Foscarnet; | 1988 |
[Cytomegaloviruses and antiviral agents--a review].
Topics: Antiviral Agents; Cytomegalovirus Infections; Foscarnet; Humans; Phosphonoacetic Acid | 1988 |
Acute renal failure induced by foscarnet: 4 cases.
Topics: Acquired Immunodeficiency Syndrome; Acute Kidney Injury; Adult; Antiviral Agents; Chorioretinitis; C | 1988 |
Effect of Foscarnet therapy on infection with human immunodeficiency virus in patients with AIDS.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Cytomegalovirus Infections; Foscarnet; HIV; HI | 1988 |
Failure of antiviral therapy for acquired immunodeficiency syndrome-related cytomegalovirus myelitis.
Topics: Acquired Immunodeficiency Syndrome; Acyclovir; Adult; Antiviral Agents; Cytomegalovirus Infections; | 1988 |
Foscarnet as treatment for cytomegalovirus retinitis following bone marrow transplantation.
Topics: Adult; Antiviral Agents; Bone Marrow Transplantation; Busulfan; Cataract; Cytomegalovirus Infections | 1988 |
Foscarnet for cytomegalovirus pneumonitis.
Topics: Adult; Cytomegalovirus Infections; Foscarnet; Humans; Male; Organophosphorus Compounds; Phosphonoace | 1985 |
Foscarnet for cytomegalovirus infections.
Topics: Antiviral Agents; Cytomegalovirus Infections; Foscarnet; Humans; Organophosphorus Compounds; Phospho | 1985 |
Foscarnet infusion at home.
Topics: Acquired Immunodeficiency Syndrome; Adult; Cytomegalovirus Infections; Foscarnet; HIV Antigens; Home | 1988 |
Intravenous foscarnet for the treatment of severe cytomegalovirus infection in allograft recipients.
Topics: Adult; Bone Marrow Transplantation; Child; Cytomegalovirus Infections; Female; Foscarnet; Humans; Im | 1985 |
Foscarnet for cytomegalovirus retinitis.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Cytomegalovirus Infections; Foscarnet; Humans; | 1985 |
Clinical experiences with phosphonoformate (foscarnet) treatment of viral diseases following renal transplantation.
Topics: Adult; Aged; Antiviral Agents; Cytomegalovirus Infections; Female; Foscarnet; Herpes Simplex; Herpes | 1985 |
Pharmacokinetics, safety and preliminary clinical experiences using foscarnet in the treatment of cytomegalovirus infections in bone marrow and renal transplant recipients.
Topics: Adult; Aged; Antiviral Agents; Bone Marrow Transplantation; Cytomegalovirus Infections; Electrolytes | 1986 |
Deoxythymidine kinase, a possible marker for monitoring activity of cytomegalovirus infection after renal transplantation.
Topics: Antiviral Agents; Cytomegalovirus Infections; Foscarnet; Humans; Kidney Transplantation; Male; Middl | 1986 |
Serum thymidine kinase in transplant patients: its relation to cytomegalovirus activity, renal transplant rejection and its use for monitoring of antiviral therapy.
Topics: Adult; Antiviral Agents; Cell Division; Cytomegalovirus Infections; Female; Foscarnet; Graft Rejecti | 1986 |
[Importance of Foscarnet in the treatment of cytomegalovirus pneumopathy in a patient with acquired immunodeficiency syndrome].
Topics: Acquired Immunodeficiency Syndrome; Adult; Antiviral Agents; Cytomegalovirus Infections; Foscarnet; | 1986 |
[Prevention and treatment of cytomegalovirus infections after graft of allogenic bone marrow].
Topics: Acyclovir; Antiviral Agents; Bone Marrow Transplantation; Cytomegalovirus Infections; Foscarnet; Gan | 1987 |
Treatment of cytomegalovirus pneumonitis with foscarnet (trisodium phosphonoformate) in patients with AIDS.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antiviral Agents; Cytomegalovirus Infections; Foscarnet; | 1987 |